Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Medicare Rx Discount Card Coalition To Employ "Share Card"

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer’s cooperative program will "ensure continuity of care" for current Share Card members and offer discounts available through other participating companies, VP Harper says. Announcement of the partnership is expected "very soon."

You may also be interested in...



Lilly Drug Access And Pricing Issues To Be Overseen By U.S. Head Santini

Gino Santini will use experience implementing the LillyAnswers drug discount card in his new position as senior VP-corporate strategy & policy. Pharmaceutical Operations Exec VP Lechleiter will assume Santini's U.S. responsibilities.

Lilly Drug Access And Pricing Issues To Be Overseen By U.S. Head Santini

Gino Santini will use experience implementing the LillyAnswers drug discount card in his new position as senior VP-corporate strategy & policy. Pharmaceutical Operations Exec VP Lechleiter will assume Santini's U.S. responsibilities.

Pfizer Medicare Discount Card Plan: Company Still Has Something Up Its Sleeve

Pfizer hoped to have its “cooperative” Medicare discount card program worked out before CMS announced the list of approved drug discount card sponsors March 25. Pfizer did not apply to sponsor an endorsed card plan, but says it will be a part of the Medicare interim discount program.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel